Brigitte Sophia W.
- Country
- Germany
- Department
- Klinik für Gynäkologie und Geburtsmedizin
Research Overview
- Phase III Randomized Study of Saruparib and Camizestrant Versus CDK4/6 Inhibitor and Endocrine Therapy in BRCA1/2 or PALB2 Mutated HR+/HER2- Advanced Breast Cancer
- Randomized Study of Trastuzumab Deruxtecan Versus Standard of Care in HER2-Positive or HER2-Low Early Breast Cancer with Molecular Relapse
Data & Insights
Has run more than one trial at 7 of 94 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in advanced breast cancer treatment, with particular emphasis on hormone receptor-positive and HER2-negative breast cancer.
- Endocrine Therapy Innovation
- Targeted Treatment Approaches
- Advanced Stage Disease Management
Their research interests encompass novel therapeutic combinations for breast cancer treatment, focusing on hormone-dependent disease progression.
Therapeutic Development
The investigator focuses on evaluating novel therapeutic combinations in oncology, particularly investigating targeted treatments for advanced breast cancer.
- Combination Therapy Assessment
- Treatment Response Evaluation
- Clinical Efficacy Studies
Their work includes assessment of progressive disease management and therapeutic effectiveness in advanced cancer settings.
Clinical Outcomes
The investigator's research concentrates on progression-free survival outcomes in advanced breast cancer patients receiving targeted therapies.
- Survival Metrics Analysis
- Treatment Effectiveness Assessment
- Patient Response Monitoring
Their expertise extends to evaluating therapeutic efficacy in hormone receptor-positive breast cancer treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.